IHL News: Incannex Appoints Principal Investigators for IHL-42X Phase 2/3 Clinical Trial - 16th Jun 2023, 10:00pm

annb0t

Top 20
Incannex Healthcare

MELBOURNE, Australia, June 16, 2023 (GLOBE NEWSWIRE) -- Incannex Healthcare Limited (Nasdaq: IXHL) (ASX: IHL), (‘Incannex’ or the ‘Company’) a clinical-stage pharmaceutical company developing unique medicinal cannabinoid pharmaceutical products and psychedelic medicine therapies for unmet medical needs, is pleased to announce that it has recruited two highly experienced lead principal investigators (PIs) for the IND opening Phase 2/3 clinical trial invest...

>>> Read more: Incannex Appoints Principal Investigators for IHL-42X Phase 2/3 Clinical Trial
 
Top Bottom